Abstract:Some major biological response modifiers (BMRs) and the potential mechanisms of platelet storage lesions (PSLs). (1) During storage, platelet morphology transforms from discoid to sphere with pseudopodia and lysis at extended storage. (2) Changes in molecules on the surface are reduced G‐protein‐coupled protease‐activated receptors (PAR4), exposure and shedding of CD42b (GPI bα) and GPVI, and inverse phosphatidylserine (PS), which are different from classical platelet activation. In parallel, α‐granules release CD62P to the membrane and soluble CD40 ligand (sCD40L) and regulated on normal activation T cells expressed and secreted (RANTES) to the extracellular space. Platelet microparticles (PMPs) are also produced by platelets. (3) These BMRs including GPI bα, GPVI, PS and PMPs may be associated with reactive oxygen species (ROS) as demonstrated by elevated O2‐ level. microRNAs (miRNAs) that may be derived from precursor miRNAs (pre‐miRNAs) and proteins that are synthesized in the existing process of translation (4) can be detected. (5) The proportion of glucose that can access the tricarboxylic acid cycle (TCA) decreases contributes to the accumulated lactate due to mitochondrial dysfunction. Background Platelet concentrate (PC) transfusions are crucial in prevention and treatment of bleeding in infection, surgery, leukemia, and thrombocytopenia patients. Although the technology for platelet preparation and storage has evolved over the decades, there are still challenges in the demand for platelets in blood banks because the platelet shelf life is limited to 5 days due to bacterial contamination and platelet storage lesions (PSLs) at 20–24°C under constant horizontal agitation. In addition, the relations between some adverse effects of platelet transfusions and PSLs have also been considered. Therefore, understanding the mechanisms of PSLs is conducive to obtaining high quality platelets and facilitating safe and effective platelet transfusions. Objective This review summarizes developments in mechanistic research of PSLs and their relationship with clinical practice, providing insights for future research. Methods Authors conducted a search on PubMed and Web of Science using the professional terms "PSL" and "platelet transfusion." The obtained literature was then roughly categorized based on their research content. Similar studies were grouped into the same sections, and further searches were conducted based on the keywords of each section. Results Different studies have explored PSLs from various perspectives, including changes in platelet morphology, surface molecules, biological response modifiers (BMRs), metabolism, and proteins and RNA, in an attempt to monitor PSLs and identify intervention targets that could alleviate PSLs. Moreover, novel platelet storage conditions, including platelet additive solutions (PAS) and reconsidered cold storage methods, are explored. There are two approaches to obtaining high‐quality platelets. One approach simulates the in vivo environment to maintain platelet activity, while the other keeps platelets at a low activity level in vitro under low temperatures. Conclusion Understanding PSLs helps us identify good intervention targets and assess the therapeutic effects of different PSLs stages for different patients.

Liposomal Resveratrol Alleviates Platelet Storage Lesion via Antioxidation and the Physical Buffering Effect

Resveratrol Prevents Endothelial Progenitor Cells from Senescence and Reduces the Oxidative Reaction Via PPAR-γ/HO-1 Pathways

Primary Study of Suppressive Effect and Mechanism of Resveratrol on Platelet Aggregation

Resveratrol Attenuates Thromboxane A2 Receptor Agonist-Induced Platelet Activation by Reducing Phospholipase C Activity.

Utilization of Mitochondrial-Targeted Small Molecules in Protecting Stored Platelets Against Storage Lesions

The Contribution of Oxidative Stress to Platelet Senescence During Storage

Shell-Sheddable Polymeric Micelles Alleviate Oxidative Stress and Inflammation for Enhanced Ischemic Stroke Therapy

Resveratrol attenuates adenosine diphosphate-induced platelet activation by reducing protein kinase C activity.

Resveratrol Confers Vascular Protection by Suppressing TLR4/Syk/NLRP3 Signaling in Oxidized Low-Density Lipoprotein-Activated Platelets

Effect of Resveratrol on Platelet Aggregation in Vivo and in Vitro

The platelet storage lesion, what are we working for?

Platelet Aggregation, Mitochondrial Function and Morphology in Cold Storage: Impact of Resveratrol and Cytochrome c Supplementation

Evaluation of Free Radical Scavenging Capacity and Antioxidative Damage Effect of Resveratrol-Nanostructured Lipid Carriers

Resolvin D1 delivery to lesional macrophages using antioxidative black phosphorus nanosheets for atherosclerosis treatment

Targeting biophysical cues to address platelet storage lesions

Platelet membrane-functionalized hollow mesoporous Prussian blue nanomedicine for comprehensive thrombolytic management by targeted enhanced fibrinolysis and ROS scavenging

Platelet storage: Progress so far

Resveratrol Reduces the Incidence of Portal Vein System Thrombosis after Splenectomy in a Rat Fibrosis Model.

Resveratrol Suppresses Lipoprotein-Associated Phospholipase A2 Expression by Reducing Oxidative Stress in Macrophages and Animal Models.

Targeted delivery and ROS-responsive release of Resolvin D1 by platelet chimeric liposome ameliorates myocardial ischemia–reperfusion injury

Precisely co-delivery of protein and ROS scavenger with platesomes for enhanced endothelial barrier preservation against myocardial ischemia reperfusion injury